Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Darolutamide, a new antiandrogen agent, was tested in men with recurrence of prostate cancer and a PSA doubling time of less than 10 months. Darolutamide was associated with metastasis-free survival of 40.4 months, as compared with 18.4 months for placebo. Toxic effects were similar in the two group...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-03, Vol.380 (13), p.1235-1246
Hauptverfasser:	Fizazi, Karim, Shore, Neal, Tammela, Teuvo L, Ulys, Albertas, Vjaters, Egils, Polyakov, Sergey, Jievaltas, Mindaugas, Luz, Murilo, Alekseev, Boris, Kuss, Iris, Kappeler, Christian, Snapir, Amir, Sarapohja, Toni, Smith, Matthew R
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Androgen Receptor Antagonists - adverse effects Androgen Receptor Antagonists - therapeutic use Androgen receptors Androgens Castration Chemotherapy Clinical trials Cognitive ability Cytotoxicity Double-Blind Method Double-blind studies Evidence-based medicine Family medical history Fatigue - chemically induced Fractures Humans Immunotherapy Intention to Treat Analysis Kaplan-Meier Estimate Male Metastases Metastasis Middle Aged Pain Progression-Free Survival Proportional Hazards Models Prostate cancer Prostate-specific antigen Prostate-Specific Antigen - blood Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - mortality Pyrazoles - adverse effects Pyrazoles - therapeutic use Quality of Life Seizures Survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Darolutamide, a new antiandrogen agent, was tested in men with recurrence of prostate cancer and a PSA doubling time of less than 10 months. Darolutamide was associated with metastasis-free survival of 40.4 months, as compared with 18.4 months for placebo. Toxic effects were similar in the two groups.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1815671